

August 16, 2011



# Pressure BioSciences, Inc. to Discuss Second Quarter 2011 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) today announced that the Company will host a teleconference to discuss its Q2 2011 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

Date: Wednesday, August 17, 2011

Time: 4:30 p.m. Eastern Daylight Time (EDT)

To attend this teleconference via web-cast, please visit the Company's website:

[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

To attend this teleconference via telephone:

Dial-in number: (888) 383-9147

For those unable to participate in the live teleconference, a replay will be accessible through the Company's website approximately one hour after the call ends through September 16, 2011.

## **About Pressure BioSciences, Inc.**

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Market listed company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology platform called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 24 issued patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced bio-molecule extraction and enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

CONTACT: Investor Contacts:  
Richard T. Schumacher, President & CEO  
Joseph Damasio, Jr., Controller  
Pressure BioSciences, Inc.

(T) 508-230-1828

Source: Pressure BioSciences, Inc.